Skip to main content
Fig. 2 | BMC Complementary and Alternative Medicine

Fig. 2

From: Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai

Fig. 2

Assessment of the therapeutic effect of SXSM on patients with bradycardia. Analysis of heart rate shows that therapeutic effect percentage is 88.14% in SXSM group and 67.34% in the control group. Total 95%CI = 3.76. Heterogeneity I2 = 0%, Z = 7.47 (P < 0.00001) in total 957 cases. Risk of bias were evaluated for each research

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us